Essential thrombocytosis

Results: 55



#Item
1NOMINATION FORM FOR MPN HEROES  NOMINATION FORM FOR MPN HEROES

NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES

Add to Reading List

Source URL: curemagazine.s3.amazonaws.com

Language: English - Date: 2015-07-10 15:12:35
21  Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62

1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62

Add to Reading List

Source URL: whobluebooks.iarc.fr

Language: English - Date: 2015-10-29 10:08:25
31  Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago

1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago

Add to Reading List

Source URL: whobluebooks.iarc.fr

Language: English - Date: 2015-10-29 10:08:25
4Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No)

Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No)

Add to Reading List

Source URL: www.shirecanada.com

Language: English - Date: 2016-03-02 15:52:12
5Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

Add to Reading List

Source URL: www.promedior.com

Language: English - Date: 2015-02-08 17:25:15
6Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

Add to Reading List

Source URL: www.novartis.ca

Language: English - Date: 2015-05-13 10:22:06
7Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre

Add to Reading List

Source URL: www.promedior.com

Language: English - Date: 2014-06-13 01:07:42
8___________________ CONTRAINDICATIONS ___________________  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing infor

___________________ CONTRAINDICATIONS ___________________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing infor

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-12-04 17:30:23
9

PDF Document

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2014-10-01 21:56:24
10Myeloproliferative Neoplasms and Somatic Mosaicism in the 23andMe Participant Community D.A. Hinds1, K.E. Barnholt1, J.L. Zehnder2, A.K. Kiefer1, C.B. Do1, N. Eriksson1, J.L. Mountain1, U. Francke1, J.Y. Tung1, R.L. Levi

Myeloproliferative Neoplasms and Somatic Mosaicism in the 23andMe Participant Community D.A. Hinds1, K.E. Barnholt1, J.L. Zehnder2, A.K. Kiefer1, C.B. Do1, N. Eriksson1, J.L. Mountain1, U. Francke1, J.Y. Tung1, R.L. Levi

Add to Reading List

Source URL: blog.23andme.com

Language: English - Date: 2012-11-08 13:25:34